Navigation Links
Good Look Ink Announces Revolutionary Hair Replication Solution
Date:5/13/2010

Non surgical procedure restores the permanent look of a full head of hair in one day.

(Vocus) May 13, 2010 -- Good Look Inc (GLI) announced a revolutionary hair replication solution recently at their Edina, Mn, office. They utilize a new process known as Cosmetic Transdermal Hair Replication that works with every hair loss solution available. It restores the permanent look of a full head of hair in one day and develops confidence and comfort in men and women who suffer from baldness, thinning, or male pattern baldness.

"What amazes me about the result is how people's confidence in themselves goes up the day they are done," said GLI Owner Darrin Gerr.

The cosmetic transdermal hair replication process is different from any other options to date. The GLI technique is a non surgical hair replication technique that mimics both the color and density of a living hair follicle. Through the use of micro pigmentation, it employs the ingraining of indelible pigment, made on the scalp. When completed, it recreates the appearance of tens of thousands of individual hair follicles and is maintenance free.

Anyone with thinning hair, any degree of baldness due to genetics, alopecia, scars from hair transplants, burn scars, hair transplant recipients with unsatisfactory results, and those who wear hair systems and wigs are candidates for cosmetic transdermal hair replication. The high cost of maintenance that goes along with other solutions is eliminated and this process is affordable and competitively priced.

"I am 28 and have had 2 transplant surgeries and was considering my third. I came in to meet with a consultant. The consultant had the cosmetic transdermal hair replication done plus, he had scars from transplant surgery," said Allen a recent customer at GLI . "Well, I couldn't see them until he showed me, and I knew this was the pla
'/>"/>

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Page: 1 2

Related medicine news :

1. Mammoth Selection Announces Revolutionary New Elite Air Purifier
2. Tattoo Removal Laser Clinic Announces New PhotoAcoustic Laser Technology
3. StopYourDrip.com Announces the Launch of a New Exercise Program to Improve Male Urinary Incontinence After Prostate Cancer Surgery
4. PHSI LLC Announces the Addition of New Technology from Audina Hearing Instruments
5. Quilmach LLC Announces the Introduction of QUILMACH.COM, the first Community Based Personal Advice Device on the Web
6. Parent Tested Parent Approved Media Announces their Winning Products for the Summer 2010 Campaign
7. Martin & Jones Announces Class Action Lawsuit Against Major Employer, Claims Thousands of Visiting Nurses Illegally Denied Overtime Pay
8. Mattress Warehouse Announces Its New Simmons Mattress Lineup
9. First Communications, Inc. Announces Audited Results for the Year Ended December 31, 2009
10. Java Planet, Tampa Bay's Newest Organic Coffee Company Announces That it Has Become Fair Trade Certified™
11. Urns.com Announces Urns As An Eco Friendly Burial Alternative
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Good Look Ink Announces Revolutionary Hair Replication Solution
(Date:9/1/2014)... September 02, 2014 Renal cell carcinoma (RCC) ... lining of the proximal convoluted tubule, a part of the ... from the blood to the urine. The condition is asymptomatic ... RCC are often in the advanced stages of the disease ... RCC often include blood in the urine, flank pain, a ...
(Date:9/1/2014)... London, UK (PRWEB) September 01, 2014 ... in developing more effective treatments for Alzheimer's disease ... disease. Uncertainties also exist regarding the diagnosis of ... hence, the lack of appropriate diagnostic tests. ... range of the greatest breakthroughs in the medicine ...
(Date:9/1/2014)... Dennis Thompson HealthDay Reporter ... experimental Ebola drug previously given to two American aid workers ... virus in laboratory tests, researchers report. The drug, ZMapp, ... if they didn,t get the medication until five days after ... Ebola who were days or even hours away from death, ...
(Date:9/1/2014)... September 01, 2014 BCC Research ( ... BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS , the global ... in 2013 and is expected to reach $38.7 million ... $471.5 million by 2019, which is equivalent to 64.9% ... The receptor-mediated transport (RMT) segment is forecasted to grow ...
(Date:9/1/2014)... September 01, 2014 Top10BestSEOHosting.com has ... many web host suppliers carefully, Top10BestSEOHosting.com is here ... the best web hosting suppliers in 2014. , ... clients with a top-of-the-line shared hosting plan. The ... easy-to-use platform that is affordable, accessible and powerful ...
Breaking Medicine News(10 mins):Health News:Renal Cell Carcinoma Market Analysis & Epidemiology Forecast to 2023 Says a New Report Available at MarketOptimizer.org 2Health News:Renal Cell Carcinoma Market Analysis & Epidemiology Forecast to 2023 Says a New Report Available at MarketOptimizer.org 3Health News:Renal Cell Carcinoma Market Analysis & Epidemiology Forecast to 2023 Says a New Report Available at MarketOptimizer.org 4Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Why Top10BestSEOHosting.com Calls Them Great Web Hosting Suppliers 2
... Recent surveys from,Centers for Disease Control and ... Epidemiology (APIC) have raised awareness of the,threat ... Staphylococcus aureus (MRSA). As the public learns,more ... simple steps,to protect themselves and loved ones ...
... NGSX ), a biopharmaceutical company focused on developing ... results for its third quarter of 2007 on Wednesday, ... call to review the results will begin at 4:30 ... will be hosted by Anthony DiTonno,President and Chief Executive ...
... overwhelming majority, 90 percent of Americans, claim a particular ... religiously diverse than ever before, which is why it ... clients beliefs stem from, says Dr. E. Thomas Dowd, ... much less religious than the general population, says Dowd. ...
... Commonwealth University researchers have discovered a new mechanism to ... clotting disorders, which could lead to novel therapies to ... in the body in areas such as the legs. ... a protein involved in coagulation, is inhibited, rendering blood ...
... - Request Provides CMS with New Scientific ... Ortho Biotech Products, L.P.,the company that ... that the Centers for Medicare and Medicaid ... (NCD) for,erythropoiesis-stimulating agents (ESAs). The company,s request ...
... the Washington,state man who,s spent more than a year walking ... to conclude his odyssey,today at the southernmost city in the ... Gregory set out from his home near the Canadian,border in ... job,with a beverage distributor to accommodate his plans. His trek ...
Cached Medicine News:Health News:Six Simple Steps to Protect Against and Stop the Spread of Superbugs 2Health News:NeurogesX to Report Third Quarter 2007 Financial Results on November 14, 2007 2Health News:NeurogesX to Report Third Quarter 2007 Financial Results on November 14, 2007 3Health News:Researchers identify molecules with interesting anti-clotting properties 2Health News:Ortho Biotech to Submit Official Request for Reconsideration to CMS Regarding ESA Coverage Policy 2Health News:Ortho Biotech to Submit Official Request for Reconsideration to CMS Regarding ESA Coverage Policy 3Health News:Ortho Biotech to Submit Official Request for Reconsideration to CMS Regarding ESA Coverage Policy 4Health News:Ortho Biotech to Submit Official Request for Reconsideration to CMS Regarding ESA Coverage Policy 5Health News:Cross-Country Walker to Finish His Journey for Cancer Research 2
(Date:8/29/2014)... 2014 According to the ... Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User ... Gene Synthesis, NGS, DNA, RNAi) - Global Forecast ... Synthesis Market is expected to reach $1,712.1 Million ... at a CAGR of 9.8% from 2014 to ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "Global Multiple Sclerosis Drugs Market 2014-2018" report to ... chronic, inflammatory medical condition that results in demyelination, axonal ... of an abnormal response by the immune system, which ... is a potentially debilitating disease in which the damage ...
(Date:8/29/2014)... British Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the ... fiscal year-end financial statements.  The Company recently changed its ... facilitate an application to list its common stock on ... DelMar,s financial statements as filed with the ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... YORK , July 7 Reportlinker.com announces that a new market research ... , Stakeholder ... , , , ... , , ...
... July 7 Scientists have used a genetically reprogrammed herpes virus ... metastatic disease in mice – still an elusive goal when treating humans ... Gene Therapy. , ... Less than 30 percent of patients with metastatic cancer survive ...
Cached Medicine Technology:Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 2Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 3Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 4Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 5Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 6Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 7Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 8Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 9Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 10Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 11Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 12Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 13Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 14Reprogrammed Herpes Virus Given Systemically Before Anti-vascular Drug Shrinks Distant Sarcomas 2Reprogrammed Herpes Virus Given Systemically Before Anti-vascular Drug Shrinks Distant Sarcomas 3Reprogrammed Herpes Virus Given Systemically Before Anti-vascular Drug Shrinks Distant Sarcomas 4
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 13.0 mm and length 15 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 9.0 mm and length 9 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 8.0 mm and length 7 mm....
... The BacT/Alert 3D Select is ... automated microbial detection system that ... and mycobacteria culturing. This system ... management or laboratory information system ...
Medicine Products: